Is Alexion stock really worth $175 a share?
This cash and stock merger agreement reportedly values Alexion at $175 a share, which represents a 45% premium compared to where the company's shares closed last Friday. The transaction is expected to close in the third quarter of 2021.
Why is Alexion Pharmaceuticals stock soaring Monday morning?
Shares of the rare-disease specialist Alexion Pharmaceuticals ( NASDAQ:ALXN) are up by a healthy 30.6% as of 10:03 a.m. EST Monday morning. The biotech's shares are roaring higher this morning in response to a $39 billion buyout agreement with British and Swedish pharma giant AstraZeneca ( NASDAQ:AZN).
What is Alexion Pharmaceuticals's return on equity?
Alexion Pharmaceuticals had a net margin of 29.64% and a return on equity of 20.23%. Alexion Pharmaceuticals's quarterly revenue was up 15.1% on a year-over-year basis. During the same quarter last year, the firm earned $2.07 earnings per share.
When will Alexion Pharmaceuticals'dividend be paid?
Shareholders of record on Monday, November 8th will be given a dividend of $4.50 per share on Friday, November 19th. This represents a $18.00 dividend on an annualized basis and a yield of 9.86%. View Alexion Pharmaceuticals' dividend history.
See more
Is Alexion Pharmaceuticals a good stock to buy?
Alexion Pharmaceuticals has received 76.39% “outperform” votes from our community.
What happened to Alexion Pharmaceuticals stock?
The Alexion shares will be delisted from the Nasdaq Stock Market and Alexion will terminate its registration under the U.S. Securities Exchange Act of 1934 as soon as practicable following completion of the acquisition.
When did AstraZeneca acquire Alexion?
The $39bn deal, announced in December 2020, is AstraZeneca's largest ever acquisition: allowing it to move further into immunology with an enhanced scientific presence, and giving it Alexion's lead medicine soliris (eculizumab), among four other approved medicines and a pipeline of 11 molecules.
Who took over Alexion?
Alexion's complement-biology platform and pipeline are to be used by AstraZeneca to develop treatments for rare diseases. AstraZeneca will enter the rare disease business with Alexion acquisition.
Did AZ buy Alexion?
AZ on Wednesday announced the completion of its Alexion acquisition, a week after securing a pivotal nod from the U.K.'s Competition and Markets Authority (CMA).
Who owns Alexion?
AstraZenecaAlexion Pharmaceuticals / Parent organizationAstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, England. Wikipedia
Is Pfizer buying AstraZeneca?
Under the terms of the agreement, Pfizer will make an upfront payment of $550 million to AstraZeneca upon the close of the transaction and a deferred payment of $175 million in January 2019.
What is Alexion known for?
Alexion Pharmaceuticals, Inc. is a biopharmaceutical company, which focuses on serving patients with devastating and ultra-rare disorders through the development and commercialization of life-transforming therapeutic products. Its products include ultomiris, soliris, strensiq and kanuma.
Did Pfizer buy AstraZeneca?
Former suitor Pfizer buys AstraZeneca firm for $1.5 billion.
Why AstraZeneca bought Alexion?
The deal gives the Cambridge-headquartered biopharmaceutical company a much greater scientific presence in the fields of rare diseases and immunology. It will prompt the creation of a rare diseases group called 'Alexion, AstraZeneca Rare Disease', headquartered in Boston, in the United States.
How did AstraZeneca acquire Alexion?
The acquisition will be undertaken through a US statutory merger in which Alexion shareholders will receive $60 in cash and 2.1243 new AstraZeneca ADSs listed on the Nasdaq exchange for each of their Alexion shares.
How much is Alexion worth?
$40.33 BillionAs of June 2022 Alexion Pharmaceuticals has a market cap of $40.33 Billion. This makes Alexion Pharmaceuticals the world's 384th most valuable company by market cap according to our data.
About Alexion Pharmaceuticals
Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.
Headlines
Was The Smart Money Right About Piling Into Microchip Technology Incorporated (MCHP)?
Alexion Pharmaceuticals (NASDAQ:ALXN) Frequently Asked Questions
3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Alexion Pharmaceuticals in the last twelve months. There are currently 2 hold ratings and 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" Alexion Pharmaceuticals stock.
What happened
Shares of the rare-disease specialist Alexion Pharmaceuticals ( ALXN ) are up by a healthy 30.6% as of 10:03 a.m. EST Monday morning. The biotech's shares are roaring higher this morning in response to a $39 billion buyout agreement with British and Swedish pharma giant AstraZeneca ( AZN 4.21% ).
So what
While it's not exactly a secret that Astra has been deal-hunting this year in an effort to meet CEO Pascal Soriot's $40 billion revenue goal by 2023, Alexion and its rare-disease drug portfolio probably weren't on most investors' radars.
Now what
Did Astra make the right move? Albeit unexpected, Astra's deep dive into the realm of rare-disease drugs actually holds a lot of promise from a growth standpoint. Alexion's annual revenue, after all, could more than double from current levels by 2025.
Premium Investing Services
Invest better with the Motley Fool. Get stock recommendations, portfolio guidance, and more from the Motley Fool's premium services.